Cancer Gene Therapy

Journal

Publication Venue For

  • CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells 2021
  • Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.  27:898-909. 2020
  • Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.  27:246-255. 2020
  • Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy 2020
  • SON inhibits megakaryocytic differentiation via repressing RUNX1 and the megakaryocytic gene expression program in acute megakaryoblastic leukemia 2020
  • The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.  23:348-354. 2016
  • Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.  22:496-505. 2015
  • Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.  22:410-416. 2015
  • Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.  22:44-54. 2015
  • Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.  21:264-274. 2014
  • Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo.  21:518-525. 2014
  • Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.  20:133-140. 2013
  • Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles.  19:545-552. 2012
  • Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development.  19:126-134. 2012
  • Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.  18:850-858. 2011
  • Oncolytic adenovirus based on serotype 3.  18:288-296. 2011
  • Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer.  17:893-905. 2010
  • Erratum: Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer (Cancer Gene Therapy (2010) 17 (893-905)).  17:906. 2010
  • CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.  16:794-805. 2009
  • Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.  16:246-255. 2009
  • A three-dimensional assay for measurement of viral-induced oncolysis.  14:421-430. 2007
  • Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.  14:45-56. 2007
  • Transductional targeting of adenovirus vectors for gene therapy.  13:830-844. 2006
  • Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents.  13:606-618. 2006
  • Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.  13:203-214. 2006
  • Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.  12:359-368. 2005
  • Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.  12:284-294. 2005
  • Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.  12:26-34. 2005
  • In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.  12:12-18. 2005
  • Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.  11:256-262. 2004
  • Enhancing antimelanoma immune responses through apoptosis.  10:726-736. 2003
  • Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential.  10:583-588. 2003
  • Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.  10:341-352. 2003
  • Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids.  10:377-387. 2003
  • Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.  10:330-339. 2003
  • Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.  10:23-29. 2003
  • Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma.  8:990-996. 2001
  • Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target.  7:1250-1256. 2000
  • Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter.  7:1120-1126. 2000
  • SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma.  7:446-455. 2000
  • Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors.  6:209-219. 1999
  • Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells.  5:331-336. 1998
  • Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.  3:89-98. 1996
  • Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo..  2:97-104. 1995
  • International Standard Serial Number (issn)

  • 0929-1903
  • Electronic International Standard Serial Number (eissn)

  • 1476-5500